- 5 additional panels beyond the SAMHSA-5: benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone (or methamphetamine as separate panel).
- THC cutoff is unchanged from a 5-panel test: 50 ng/mL immunoassay, 15 ng/mL GC-MS confirmation.
- Benzodiazepines are the most impactful addition — any prescription benzo (Xanax, Valium, Klonopin, Ativan) produces a true positive on this panel.
- Government, law enforcement, and healthcare are the most common 10-panel users due to controlled substance access and safety requirements.
- The MRO process can clear legitimate prescription positives — disclose all medications before the test, not after a positive result.
- 12-panel adds oxycodone and MDMA; 16-panel further adds fentanyl, tramadol, buprenorphine, and ketamine.
- Poppy seeds genuinely cause false positives for opiates at elevated consumption — the bagel defense is real and MRO-recognized.
The Complete 10-Panel Substance Reference
Each panel targets a specific drug class using immunoassay antibodies calibrated to the primary drug compound or its major metabolite. The table below provides complete cutoff and detection data for all 10 substance categories as defined under SAMHSA Mandatory Guidelines and standard occupational testing protocols.
| # | Substance | Target Metabolite | IA Cutoff | GC-MS Cutoff | Detection Window |
|---|---|---|---|---|---|
| 1 | Cannabis (THC) | THC-COOH | 50 ng/mL | 15 ng/mL | 1–3 days (single); up to 90 days (heavy daily) |
| 2 | Cocaine | Benzoylecgonine | 150 ng/mL | 100 ng/mL | 2–4 days (typical); up to 1 week heavy use |
| 3 | Opiates | Morphine / Codeine | 2000 ng/mL | 2000 ng/mL | 2–4 days |
| 4 | Amphetamines | Amphetamine | 500 ng/mL | 250 ng/mL | 2–4 days |
| 5 | Phencyclidine (PCP) | Phencyclidine | 25 ng/mL | 25 ng/mL | 7–14 days (single); up to 30 days (chronic) |
| 6 | Benzodiazepines | Oxazepam / Nordiazepam | 200 ng/mL | 200 ng/mL | 3–7 days (short-acting); 2–6 weeks (long-acting, e.g. Valium) |
| 7 | Barbiturates | Butalbital / Phenobarbital | 200 ng/mL | 200 ng/mL | 2–4 days (short-acting); 2–3 weeks (phenobarbital) |
| 8 | Methadone | Methadone / EDDP | 300 ng/mL | 100 ng/mL | 3–8 days |
| 9 | Propoxyphene | Norpropoxyphene | 300 ng/mL | 200 ng/mL | 6–48 hours |
| 10 | Methaqualone (or Methamphetamine) | Methaqualone / Methamphetamine | 300 ng/mL / 500 ng/mL | 200 ng/mL / 250 ng/mL | 24–72 hours / 3–5 days |
5-Panel vs. 10-Panel vs. 12-Panel vs. 16-Panel
The panel number reflects how many distinct substance classes are simultaneously screened on a single urine specimen. More panels means broader screening, higher cost, and more opportunities for prescription medication conflicts requiring MRO review. The choice of panel is driven by industry regulation, liability exposure, and the specific substance abuse risk profile of the role being tested.
| Panel Type | Substances Included | Typical Cost | Primary Use Case |
|---|---|---|---|
| 5-Panel (SAMHSA-5) | THC, Cocaine, Opiates, Amphetamines, PCP | $15–$30 | Standard pre-employment; federal DOT baseline |
| 10-Panel | SAMHSA-5 + Benzodiazepines, Barbiturates, Methadone, Propoxyphene, Methaqualone | $40–$80 | Government, law enforcement, healthcare, executive roles |
| 12-Panel | 10-Panel + MDMA/Ecstasy, Oxycodone | $55–$100 | Healthcare, high-risk safety-sensitive, addiction medicine |
| 16-Panel | 12-Panel + Fentanyl, Tramadol, Buprenorphine, Ketamine | $80–$150 | Court-ordered monitoring, addiction treatment programs, high-security positions |
Industries That Require 10-Panel Testing
The decision to order a 10-panel test rather than the standard 5-panel is driven by three primary factors: regulatory mandate, controlled substance access risk, and industry liability profile. Industries where employees have access to controlled substances or make safety-critical decisions under potential influence have the strongest rationale for expanded panel testing.
| Sector | Typical Panel | Primary Substances of Concern (Beyond SAMHSA-5) | Regulatory Authority |
|---|---|---|---|
| Law enforcement agencies | 10–12 panel | Benzodiazepines, barbiturates (armed officer impairment) | Agency policy; no single federal mandate |
| Federal government (national security) | 10 panel | Benzodiazepines, barbiturates, methadone | SAMHSA / OPM Mandatory Guidelines |
| Healthcare — hospitals, nursing homes | 10–12 panel | Benzodiazepines, opioids, barbiturates (diversion risk) | CMS, JCAHO accreditation requirements, employer policy |
| Nuclear power facilities | 10 panel (minimum) | Benzodiazepines (sedation risk in safety-critical environment) | NRC 10 CFR Part 26 |
| Professional sports (MLB, NFL, NBA) | Varies by CBA | Amphetamines (stimulant performance), barbiturates | League collective bargaining agreement |
| Private executive / senior management | 10 panel optional | Benzodiazepines, barbiturates | Employer discretion |
| Aviation (beyond DOT minimum) | 10 panel some carriers | Benzodiazepines (pilot impairment risk) | FAA baseline is 5-panel; airlines may expand |
Detection Windows by Substance
Detection windows vary significantly across the 10 panels depending on the metabolic half-life of each compound, its fat-solubility, and the individual’s renal clearance rate. Cannabis has the widest range due to its fat-soluble storage mechanism. The benzodiazepine panel has a particularly wide range because short-acting benzos (Xanax, Ativan) clear in days while long-acting benzos (Valium, Librium) can persist for weeks in chronic users.
| Substance | Single Use Detection | Moderate Use Detection | Chronic Use Detection | Key Variable |
|---|---|---|---|---|
| Cannabis (THC) | 1–3 days | 5–10 days | 30–90+ days | Body fat percentage; frequency |
| Cocaine | 2–3 days | 3–5 days | Up to 14 days | Heavy binge use extends window significantly |
| Opiates (morphine/codeine) | 2–3 days | 3–4 days | Up to 7 days | Dose; codeine partially converts to morphine |
| Amphetamines | 1–2 days | 2–4 days | Up to 7 days | Urine pH; alkaline urine extends detection |
| PCP | 7–14 days | Up to 14 days | Up to 30 days | Highly fat-soluble; long half-life |
| Benzodiazepines (short-acting) | 1–3 days | 3–7 days | Up to 2 weeks | Xanax, Ativan: short half-life |
| Benzodiazepines (long-acting) | 7–14 days | 2–4 weeks | 4–6 weeks | Valium, Librium: active metabolites accumulate |
| Barbiturates (short-acting) | 24 hours–3 days | 2–4 days | Up to 3 weeks | Phenobarbital has 2–3 week window |
| Methadone | 3–5 days | 3–8 days | Up to 2 weeks | Maintenance dosing: consistent detection |
| Propoxyphene | 6–24 hours | Up to 48 hours | 2–3 days | Very short detection window; rapid clearance |
False Positives on the Expanded Panels
The benzodiazepine and opiate panels carry the highest false positive and prescription-interaction risk. For any confirmed positive on a 10-panel test, the MRO contacts the employee before reporting to the employer. This is the critical window to provide prescription documentation. Disclosing medications proactively — before a positive result comes back — is always preferable to disclosing after.
| Panel | False Positive Risk | Common Causes | MRO Clearable with Rx? |
|---|---|---|---|
| Benzodiazepines | High (for Rx users) | Xanax, Valium, Klonopin, Ativan, Restoril (all true positives if prescribed) | Yes, with valid prescription |
| Amphetamines | Moderate (for Rx users) | Adderall, Vyvanse, Ritalin (true positive if prescribed); pseudoephedrine (weak, rare) | Yes, with valid prescription |
| Opiates | Moderate | Poppy seeds (high volume); prescription codeine, tramadol (true positive) | Yes; poppy seed defense accepted with MRO discretion |
| Methamphetamine | Low | Vicks nasal inhaler (l-methamphetamine, not d-methamphetamine); selegiline (Parkinson’s Rx) | Yes, with documentation; GC-MS can distinguish isomers |
| Barbiturates | Low (for Rx users) | Phenobarbital (epilepsy Rx), butalbital (Fioricet) (true positives if prescribed) | Yes, with valid prescription |
| Cannabis (THC) | Very Low | Dronabinol / Marinol (Schedule III synthetic THC Rx) | Yes, with valid Rx |
| PCP | Very Low | High-dose dextromethorphan (DXM) in some cross-reactivity studies; rare | Context-dependent; GC-MS distinguishes |
| Methadone | Very Low | Rare diphenhydramine cross-reactivity at very high doses | Yes, context-dependent |
The MRO Process: Your Rights After a Positive Result
The Medical Review Officer is a licensed physician whose specific role in the federal drug testing framework is to review all confirmed positive laboratory results before they are reported to the employer. The MRO is required to contact the employee directly — typically by phone — and provide an opportunity to explain any legitimate medical reason for the result.
This MRO interview is confidential. The employer does not participate and is not informed of the conversation content. If the MRO determines that a valid prescription explains the positive result, the result may be reported to the employer as negative — the employer never sees the original positive. If the MRO cannot verify the prescription or the explanation is insufficient, the result is reported as confirmed positive.
Practical guidance: if you take any prescription benzodiazepines, stimulants, opioids, or barbiturates, keep your prescription bottle or pharmacy printout accessible. Have your prescribing physician’s contact information available. Do not wait until you receive a positive result to gather this documentation — the MRO timeline is tight and failing to respond to MRO contact within the required window may result in automatic positive reporting.
For cannabis specifically, being tested with a 10-panel rather than a 5-panel changes nothing. The THC-COOH cutoff is 50 ng/mL (immunoassay) and 15 ng/mL (GC-MS confirmation) — identical to the 5-panel SAMHSA standard. Detection windows are the same. The expanded panels do not make the cannabis panel more or less sensitive. If you pass the cannabis panel on a 5-panel, you pass it on a 10-panel.
Frequently Asked Questions
What does a 10-panel drug test screen for?
Cannabis, cocaine, opiates, amphetamines, PCP, benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone (or methamphetamine as a separate panel depending on the lab). Same THC cutoff (50 ng/mL immunoassay, 15 ng/mL GC-MS) as a standard 5-panel.
Who requires a 10-panel drug test?
Government agencies, law enforcement departments, healthcare employers with controlled substance access, nuclear power facilities (NRC-regulated), professional sports organizations, and some private employers in safety-sensitive roles. The 10-panel is chosen when broader substance monitoring beyond the SAMHSA-5 is required.
Can prescription medications cause a positive on a 10-panel test?
Yes. Prescription benzodiazepines, stimulants (Adderall), opioids, and barbiturates all produce true positive results on their respective panels. These are not false positives — the substances are genuinely present. The MRO can verify a valid prescription and report the result to the employer as negative with a legitimate medical explanation.
What is the difference between a 5-panel and a 10-panel drug test?
A 5-panel test (SAMHSA-5) screens for THC, cocaine, opiates, amphetamines, and PCP. A 10-panel adds benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone. The cannabis cutoff and detection sensitivity is identical in both. The 10-panel is more expensive and used when broader substance monitoring is required.